Взаимосвязь между вирусом SARS-COV-2 и аутоиммунными неврологическими заболеваниями

С начала массового распространения инфекции, вызванной вирусом SARS-CoV-2, возросло количество сообщений об увеличении частоты аутоиммунных неврологических расстройств. Предполагается, что подобное повышение уровня заболеваемости может возникать вследствие аномального иммуноопосредованного ответа организма на патогенное воздействие SARS-CoV-2. В данной статье рассматривается возможность влияния вируса SARS-CoV-2 на возникновение и обострение течения аутоиммунных неврологических расстройств, обсуждаются возможные патогенетические факторы и механизмы, анализируются особенности клинической картины и терапии. Представлены зарубежные и российские научные данные, клинические наблюдения случаев синдрома Гийена – Барре, рассеянного склероза, острого диссеминированного энцефаломиелита, миастении и других аутоиммунных заболеваний, возникших или изменивших свое типичное течение на фоне COVID-19.

1. Center for Systems Science and Engineering // COVID-19 content portal. URL:www.systems.jhu.edu/research/public-health/ncov/ (дата обращения: 09.05.2022). Saad I. COVID-19: breaking down a global health crisis / Saad I. [et al.] // Ann Clin Microbiol Antimicrob. – 2021. Vol.20, №35.

2. Galea M. Neurological manifestations and pathogenic mechanisms of COVID-19 / Galea M. [et al.] // Neurological Research. – 2022. – Р. 1-12.

3. Лобзин, Ю.В. COVID-19-ассоциированный педиатрический мультисистемный воспалительный синдром / Ю.В. Лобзин [и др.] // Медицина экстремальных ситуаций. – 2021. – № 2. – С. 13–19.

4. Mahboubi M. Neurological complications associated with Covid-19; molecular mechanisms and therapeutic approaches / Mahboubi M. [et al.] // // Reviews in Medical Virology. – 2022. – Р. e2334.

5. Manzano G. Acute disseminated encephalomyelitis and acute hemorrhagic leukoencephalitis following COVID-19: systematic review and meta-synthesis / Manzano G. [et al.] // Neurology Neuroimmunology Neuroinflammation. – 2021. Vol.8, №6. – Р. e1080.

6. Ariño H. Neuroimmune disorders in COVID-19 / Ariño H. [et al.] // Journal of Neurology. – 2022. – Р. 1-13.

7. Molina А.Е. SARS-CoV-2, a new causative agent of Guillain-Barré syndrome? / Molina А.Е. [et al.] // Med Intensiva. – 2022. – Vol.46, № 2. – Р. 110-111. Abu-Rumeileh S. Guillain–Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases / Abu-Rumeileh S. [et al.] // Journal of neurology. 2021. – Vol.268, № 4. – Р. 1133-1170.

8. Dalakas M.C. Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease: More to come with myositis in the offing / Dalakas M.C. // Neurology Neuroimmunology Neuroinflammation. – 2020. – Vol.7, №5.

9. Seyede M. Guillain-Barré/Miller Fisher overlap syndrome in a patient after coronavirus disease-2019 infection: a case report / Seyede M. [et al.] // J Med Case Rep. – 2022. – Vol.16,№1.

10. Keddie S. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome / Keddie S. // Brain. – 2021. – Vol.144,№2. – Р. 682-693.

11. Sriwastava S. Guillain Barré Syndrome and its variants as a manifestation of COVID-19: A systematic review of case reports and case series / Sriwastava S. [et al.] // Journal of the neurological sciences. – 2021. – Vol. 15, №420. – Р. 117263.

12. Laved A. Neurological associations of SARS-cov-2 infection: a systematic review / Laved A. // CNS Neurol Disord Drug Targets. – 2022. – Vol. 21, №3. – P. 246-258.

13. Mohammad А. Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review / Mohammad А. [et al.] // Can J Neurol Sci. – 2022. – №1. – P. 1-11.

14. Finsterer J. Guillain-Barré syndrome is immunogenic in SARS-CoV-2 infected / Finsterer J. [et al.] // J Med Virol. 2022. – Vol. 94, №1. – P. 22-23.

15. Marie I. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature / Marie I. [et al.] // British Journal of Dermatology. 2006. – №4. – Р. 714-721.

16. Hoepner R. Is COVID-19 severity associated with reduction in T lymphocytes in anti-CD20-treated people with multiple sclerosis or neuromyelitis optica spectrum disorder? / Hoepner R. [et al.] // CNS Neurosci Ther. – 2022. – Vol.28, №6. – P.971-973.

17. Xia H. Evasion of type I interferon by SARS-CoV-2 / Xia H. [et al.] // Cell reports. – 2020. – Vol. 33, №1. – Р. 108234.

18. Sormani M. DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France / Sormani M. [et al.] // Annals of Clinical and Translational Neurology. – 2021. – Vol.8, №8. Р. 1738-1744.

19. Finsterer J. SARS-CoV-2 triggered relapse of multiple sclerosis / Finsterer J. // Clin Neurol Neurosurg. – 2022. №215. – Р.207-210.

20. Alroughani R. Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: an observational study in the Middle East / Alroughani R. [et al.] // J Clin Neurosci. – 2022. – №99. – P. 311-316.

21. Wang Y. SARS-CoV-2-associated acute disseminated encephalomyelitis: a systematic review of the literature / Wang Y. [et al.] // Journal of Neurology. – 2021. – Р.1-22.

22. Wang C. Assessment and management of acute disseminated encephalomyelitis (ADEM) in the pediatric patient / Wang C. // Pediatric Drugs. – 2021. – Vol.23(3);213-221.

23. Esmaeili S. Acute disseminated encephalitis (ADEM) as the first presentation of COVID-19; a case report / Esmaeili S. [et al.] // Ann Med Surg (Lond). – 2022. – №77. – P. 103511.

24. Gilhus N.E. Myasthenia gravis: subgroup classification and therapeutic strategies / Gilhus N.E., Verschuuren J. // Lancet Neurol. 2015; Vol.14, №10. – Р. 1023-36.

25. Baig A.M. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms / Baig A.M. [et al.] // ACS Chem Neurosci. – 2020. – Vol.11, №7. – Р.995-998.

26. Liu R. Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia / Liu R. [et al.] // Eur J Immunol. – 2010. – Vol.40, №6. – Р. 1577-89.

27. Thiruppathi M. Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis / Thiruppathi M. [et al.] // Clin Immunol. – 2012. Vol.145, №3. – Р. 209-2.

28. Gunes H. What chances do children have against COVID-19? Is the answer hidden within the thymus? / Gunes H. [et al.] // European journal of pediatrics. – 2021. – Vol.180, №3. – Р. 983-986.

29. Wang W. High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients / Wang W., Su B., Pang L, Qiao L. // Cell Mol Immunol. – 2020. – Vol.17, №6. – Р. 650-652.

30. Quin C. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China / Quin C., Zhou L., Hu Z. // Clin Infect Dis. – 2020. – Vol.71, №15. – Р. 762-768.

31. Muir R. Innate lymphoid cells are the predominant source of IL-17A during the early pathogenesis of acute respiratory distress syndrome / Muir R., Osbourn M., Dubois A.V. // Am J Respir Crit Care Med. – 2016. – Vol.193, №4. – Р. 407-16.

32. Sriwastava S. New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review / Sriwastava S., Tandon M., Kataria S. // J Neurol. – 2021. – Vol.268, №8. – Р. 2690-2696.

33. Brossard-Barbosa N. Seropositive ocular myasthenia gravis developing shortly after COVID-19 infection: report and review of the literature / Brossard-Barbosa N. [et al.] // J Neuroophthalmol. – 2022.

34. Алексеева, Т.М. Дебют генерализованной миастении после перенесенной новой коронавирусной инфекции (COVID-19) / Т.М. Алексеева [и др.] // Журнал инфектологии. – 2021. – Т.13, № 4. – С. 127–132.

35. Jakubíkova M. Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival / Jakubíkova M., Tyblova M., Tesar A., Horakova M. // Eur J Neurol. – 2021. – Vol.28, №10. – Р. 3418-3425.

36. Kim Y. Outcomes in myasthenia gravis patients: analysis from electronic health records in the United States / Kim Y. [et al.] // Front Neurol. – 2022.

37. Muppidi S. COVID-19-associated risks and effects in myasthenia gravis (CARE-MG) / Muppidi S. [et al.] // Lancet Neurol. – 2020. – Vol.19, №12. – Р. 970-971.

38. Emamikhah M. Opsoclonus-myoclonussyndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature / Emamikhah M. [et al.] // Journal of neurovirology. – 2021. – Vol.1, №9.

39. Urrea-Mendoza E. Opsoclonus-Myoclonus-Ataxia Syndrome (OMAS) associated with SARS-CoV-2 infection: post-infectious neurological complication with benign prognosis / UrreaMendoza E., Okafor K. // J Neurovirol. – 2021. – Vol.11, №7.

40. Fernandes J. Opsoclonus myoclonus ataxia syndrome in severe acute respiratory syndrome coronavirus-2 / Fernandes J., Puhlmann P. // Journal of Neurovirology. – 2021. – Vol.1, №3.

41. Roman G. Acute transverse myelitis (ATM. clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222) / Roman G., Gracia F. // Frontiers in immunology. – 2021. – Vol.12, №879.